← back to search

Brandon Essink

Velocity Clinical Research (United States) · US
Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, Respiratory viral infections research, Animal Virus Infections Studies, and COVID-19 Clinical Research Studies.
h-index
29
citations
3,751
works
78
NIH funding
primary concept
Immunogenicity
email

Recent publications

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons
Clinical Infectious Diseases 2024cited by 154position: middledoi
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases
Nature Communications 2024cited by 35position: middledoi
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study
Human Vaccines & Immunotherapeutics 2024cited by 4position: firstdoi
Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions
Clinical Infectious Diseases 2023cited by 52position: middledoi
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial
The Journal of Infectious Diseases 2022cited by 117position: middledoi
Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
Nature Medicine 2022cited by 36position: middledoi
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
New England Journal of Medicine 2021cited by 655position: middledoi
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
The Lancet Infectious Diseases 2021cited by 123position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Weiping Deng · Yunnan Agricultural University2 papers (2022–2024)Bethany Girard · Scleroderma Foundation2 papers (2022–2024)Edward Kerwin · Novartis (Switzerland)2 papers (2022–2022)Hana M. El Sahly · Baylor College of Medicine2 papers (2022–2024)Joanne E. Tomassini · Moderna Therapeutics (United States)2 papers (2022–2024)Ian Frank · Future University Hakodate2 papers (2021–2022)Lindsey R. Baden · Harvard University2 papers (2022–2024)Olaf‐Oliver Wolz · University of Tübingen1 papers (2024–2024)Sanjay Gurunathan · Sanofi (United States)1 papers (2021–2021)Roger Masotti · Sanofi (United States)1 papers (2021–2021)Stefano Berrè · Institut Pasteur1 papers (2024–2024) · 1 papers (2022–2022)Spiros Miyakis · University of Wollongong1 papers (2024–2024)Corinne Vandermeulen · KU Leuven1 papers (2022–2022)Nancy Dezutter · GlaxoSmithKline (Belgium)1 papers (2022–2022)Anne-Laure Chabanon · National Patient Safety Foundation1 papers (2021–2021)Stephen J. Savarino · Sanofi (United States)1 papers (2021–2021)Susanne Doblecki‐Lewis · University of Miami1 papers (2024–2024) · 1 papers (2024–2024)Avika Dixit · Indiana University School of Medicine1 papers (2024–2024)